Heart Surgery News and Research

RSS

Heart surgery is done to correct problems with the heart. More than half a million heart surgeries are done each year in the United States for a variety of heart problems. Heart surgery is used to correct heart problems in children and adults. This article discusses heart surgeries for adults. For more information about heart surgeries for children, see the Diseases and Conditions Index articles on congenital heart defects, holes in the heart, and tetralogy of Fallot.

The most common type of heart surgery for adults is coronary artery bypass grafting (CABG). During CABG, surgeons use healthy arteries or veins taken from another part of the body to bypass (that is, go around) blocked arteries. CABG relieves chest pain and reduces the risk of heart attack.

Stem cell model could provide insights into biological mechanisms that underlie neuropsychiatric disorders

Researchers from the Icahn School of Medicine at Mount Sinai have applied a novel stem cell model to map disease risk variants in human neurons, which could help provide insights into the biological mechanisms that underlie neuropsychiatric disorders such as autism and schizophrenia.

1 Jun 2022

Study shows how stress has a major impact on the immune system's ability to fight infections

Acute stress can be detrimental to fighting off infection, especially COVID-19, and increases the chance of dying in mouse models.

30 May 2022

Reduced exercise capacity is common in long COVID patients

In a recent study posted to the medRxiv* preprint server, researchers illustrated cardiac findings in coronavirus disease 2019 (COVID-19)-recovered individuals more than a year after infection.

22 May 2022

Multi-center trial shows promising results for implant-free interatrial shunt device to treat heart failure patients

Results from early clinical evaluation of the Alleviant System to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions.

20 May 2022

Study validates long-term safety and efficacy of Harmony transcatheter pulmonary valve implant

A study of one year outcomes in the largest cohort to date of Harmony transcatheter pulmonary valve (TPV) patients with congenital heart disease (CHD) and severe pulmonary regurgitation (PR) was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions 2022 Scientific Sessions.

19 May 2022

Children's Colorado first in the world to implant the newly FDA-approved G-Armor Stent

Children's Hospital Colorado (Children's Colorado) is the first hospital in the world to implant the newly FDA-approved G-Armor Stent. Although the stent is designed to be used in the smallest of patients, it was first implanted in a Colorado father of two.

18 May 2022

Early valve replacement surgery could benefit patients with aortic stenosis

Valve replacement heart surgery should be performed earlier than conventionally thought for people with aortic stenosis – according to new research from the University of East Anglia.

18 May 2022

Less invasive procedure for common heart condition just as effective as conventional open-heart surgery

A study led by researchers at the National Institute for Health and Care Research Leicester Biomedical Research Centre has shown that a less invasive heart procedure for a common condition is just as effective as conventional open-heart surgery.

17 May 2022

Immunotherapy after bladder cancer surgery helps reduce cancer recurrence

Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results presented at the American Urological Association annual meeting in May.

15 May 2022

New therapeutic approach for cardiac repair after a heart attack

Following a heart attack, the human body is incapable of repairing lost tissue due to the heart's inability to generate new muscle.

12 May 2022

Researchers reveal how not-yet-malignant cells “turn on” and become metastatic breast cancer

Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, "turn on" and become metastatic breast cancer.

26 Apr 2022

Mount Sinai wins $500,000 grant to support continued innovation in pancreatic cancer treatment

The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued innovation in its multidisciplinary treatment of pancreatic cancer.

19 Apr 2022

The Mount Sinai Hospital completes full renovation of its children's ED

The Mount Sinai Hospital has announced the completion of a full renovation of its children's Emergency Department (ED), and a newly redesigned area for walk-in, low acuity adult patients.

11 Apr 2022

Study captures the immune effect of COVID-19 vaccine in patients with multiple myeloma

Most immunocompromised people with a blood cancer called multiple myeloma benefited from a third dose of COVID-19 vaccines, a promising sign after it was shown that two doses tended to not be sufficient for them.

6 Apr 2022

Novel transcatheter repair system for tricuspid regurgitation shows promising results at one year

Patients with tricuspid regurgitation, a common and debilitating form of valvular heart disease, who received a novel investigational device intended to repair the defective valve experienced significant improvements in blood flow through the heart and in quality of life at one year, according to research presented at the American College of Cardiology's 71st Annual Scientific Session.

5 Apr 2022

Extension study shows mavacamten’s efficacy and safety in treating hypertrophic cardiomyopathy

Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, resulted in continued benefits in patient quality of life and outcomes over an extended period of time, according to interim data from the EXPLORER-HCM extension study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

New drug shows promise in relieving symptoms associated with hypertrophic cardiomyopathy

A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C.

3 Apr 2022

Experimental drug for hypertrophic cardiomyopathy reduces the need for invasive procedures, trial shows

Findings from a Cleveland Clinic-led clinical trial showed that the use of an experimental drug in severely symptomatic, hypertrophic cardiomyopathy patients significantly reduced the need for invasive procedures.

2 Apr 2022

NIH program provides a real-time risk assessment of variants of SARS-CoV-2

Faculty from the Departments of Microbiology, Medicine Genetics and Genomic Sciences, and Pathology and Molecular Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai play key roles in a National Institutes of Health (NIH) program set up to provide a real-time risk assessment of variants of SARS-CoV-2, the virus that causes COVID-19. The program, called SARS-CoV-2 Assessment of Viral Evolution (SAVE) and described in a paper published March 31 in Nature, assesses how the variants might affect transmission, virulence, and resistance to both disease-induced (convalescent) and vaccine-induced immunity.

31 Mar 2022

$Metabolic-immune interaction appears to be the cause of heart failure with preserved ejection fraction$

Metabolic-immune interaction appears to be the cause of heart failure with preserved ejection fraction

The dominant form of heart failure worldwide appears to be caused by a strong, bidirectional interaction between the body's response to metabolic stress and the immune system, according to a review article written by UT Southwestern researchers and colleagues.

23 Mar 2022